Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial

B Strober; JG Krueger; N Magnolo; R Vender; DP Toth; D Thaci; M Wang; C Cioffi; C Madden; RB Warren

doi:10.25251/skin.5.supp.16

B Strober

Yale University, New Haven, CT, USA; Central Connecticut Dermatology Research, Cromwell, CT, USA

JG Krueger

The Rockefeller University, New York, NY, USA

N Magnolo

Universitatsklinikum Munster, Munster, Germany

R Vender

McMaster University, Hamilton, ON, Canada

DP Toth

Probity Medical Research; Windsor, ON, Canada

D Thaci

Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lubeck, Lubeck, Germany

M Wang

UCB Pharma, Raleigh, NC, USA

C Cioffi

UCB Pharma, Raleigh, NC, USA

C Madden

UCB Pharma, Raleigh, NC, USA

RB Warren

Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK

Keywords

Plaque Psoriasis, Bimekizumab, IL-17A, IL-17F, Ustekinumab

Abstract

Abstract not available.

References

1. Durham L. Curr Rheumatol Reports 2015;17:55

2. Fujishima S. Arch Dermatol Res 2010;302:499–505

3. Glatt S. Br J Clin Pharmacol 2017;83:991–1001

4. Papp KA. J Am Acad Dermatol 2018;79:277–86.e10

5. Kamiya K. Int J Mol Sci 2019;20:4347.

Poster PDF

Published

Jan 1, 2021

DOI https://doi.org/10.25251/skin.5.supp.16

How to Cite

[1]

Strober, B., Krueger, J., Magnolo, N., Vender, R., Toth, D., Thaci, D., Wang, M., Cioffi, C., Madden, C. and Warren, R. 2021. Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial. SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s16. DOI:https://doi.org/10.25251/skin.5.supp.16.

Issue

Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)

Section

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

KA Papp, M Lebwohl, AB Gottlieb, M Sebastian, R Langley, Y Okubo, M Wang, C Cioffi, F Staelens, K Reich, Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
RB Warren, C Conrad, P Foley, L Iversen, RG Langley, G Kokolakis, L Davis, V Vanvoorden, S Wiegratz, JF Merola, Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
RB Warren, A Blauvelt, J Bagel, KA Papp, P Yamauchi, A Armstrong, R Langley, V Vanvoorden, D De Cuyper, L Peterson, N Cross, K Reich, Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE) , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
K Reich, K Papp, A Blauvelt, R Langley, A Armstrong, RB Warren, K Gordon, JF Merola, C Madden, M Wang, V Vanvoorden, M Lebwohl, Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
K Reich, A Blauvelt, M Lebwohl, KA Papp, P Rich, B Strober, D De Cuyper, C Madden, L Peterson, V Vanvoorden, RB Warren, Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
K Gordon, P Foley, JG Krueger, A Pinter, K Reich, R Vender, V Vanvoorden, C Madden, L Peterson, A Blauvelt, Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
K Gordon, P Foley, P Rich, K Duffin, A Pinter, CEM Griffiths, M Wang, V Vanvoorden, F Staelens, V Ciaravino, JF Merola, Bimekizumab Versus Ustekinumab in Plaque Psoriasis: Lasting Efficacy Translates to Rapid and Sustained Improvements in Quality of Life in the BE VIVID Multicenter, Randomized, Double-Blinded Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
A Blauvelt, KC Duffin, N Magnolo, J Weisman, M Ståhle, D Wilsmann-Theis, M Wang, K Wixted, B Szilagyi, L Puig, Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT) , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
E von Stebut, K Reich, D Thaci, W Koenig, A Pinter, A Korber, T Rassaf, A Waisman, V Mani, D Yates, J Frueh, C Sieder, N Melzer, T Gori, Secukinumab Reduces Endothelial Dysfunction in Subjects with Moderate-to-Severe Plaque Psoriasis Over 52 Weeks: Results of the Exploratory CARIMA Study , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
D Tha?i, A Blauvelt, K Reich, RB Warren, V Piguet, F Brock, F Fierens, V Ciaravino, M Lebwohl, Long-Term Improvements in Health-Related Quality of Life of Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Results from the CIMPASI-1 and CIMPASI-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)

1 2 3 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)